> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rhythm Pharma Granted Priority Review Voucher
- URL: https://www.fdaweb.com/rhythm-pharma-granted-priority-review-voucher/
- Published: 2020-12-16T12:00:00.000Z
- Updated: 2026-09-14T16:40:32.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148312

*Federal Register* notice: FDA has announced the issuance of a priority review voucher to Rhythm Pharmaceuticals related to its rare pediatric disease product NDA for Imcivree (setmelanotide) injection, indicated for treating chronic weight management in adult and pediatric patients six years of age and older with proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency obesity. To view the notice, click [here](https://public-inspection.federalregister.gov/2020-27760.pdf?ref=fdaweb.com).